{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:40:08Z","timestamp":1790710808167,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Polymyxin B hemadsorption (PMX-HA) reduces blood endotoxin levels, but characteristics of patients with sepsis likely to benefit from PMX-HA are not well known. We sought to identify patient subgroups likely to benefit from PMX-HA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively identified 1911 patients with sepsis from a retrospective observational study in Japan (the JSEPTIC-DIC study) and 286 patients with endotoxemic septic shock from a randomized controlled trial in North America that restricted patients to those with high endotoxin activity (the EUPHRATES trial). We applied the machine learning-based causal forest model to the JSEPTIC-DIC cohort to investigate heterogeneity in treatment effects of PMX-HA on 28-day survival after adjusting for potential confounders and ascertain the best criteria for PMX-HA use. The derived criteria for targeted therapy by PMX-HA were validated using the EUPHRATES trial cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The causal forest model revealed heterogeneity in treatment effects of PMX-HA. Since patients having higher treatment effects were more likely to have severe coagulopathy and hyperlactatemia, we identified the potential treatment targets of PMX-HA as patients with PT-INR\u2009&gt;\u20091.4 or lactate\u2009&gt;\u20093\u00a0mmol\/L. In the EUPHRATES trial cohort, PMX-HA use on the targeted subpopulation (75% of all patients) was significantly associated with higher 28-day survival (PMX-HA vs. control, 68% vs. 52%; treatment effect of PMX-HA, +\u200916% [95% CI\u2009+\u20092.2% to\u2009+\u200930%], <jats:italic>p<\/jats:italic>\u2009=\u20090.02).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Abnormal coagulation and hyperlactatemia in septic patients with high endotoxin activity appear to be helpful to identify patients who may benefit most from PMX-HA. Our findings will inform enrollment criteria for future interventional trials targeting patients with coagulopathy and hyperlactatemia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-023-04533-3","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T12:02:20Z","timestamp":1687348940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Itsuki","family":"Osawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineji","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kushimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra M.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kellum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"issue":"8","key":"4533_CR1","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1177\/1753425913516885","volume":"20","author":"T Ikeda","year":"2014","unstructured":"Ikeda T, Ikeda K, Suda S, Ueno T. Usefulness of the endotoxin activity assay as a biomarker to assess the severity of endotoxemia in critically ill patients. Innate Immun. 2014;20(8):881\u20137.","journal-title":"Innate Immun"},{"issue":"3","key":"4533_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1086\/422254","volume":"190","author":"JC Marshall","year":"2004","unstructured":"Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004;190(3):527\u201334.","journal-title":"J Infect Dis"},{"issue":"1","key":"4533_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/JTCCM-D-22-00015","volume":"4","author":"J Kellum","year":"2022","unstructured":"Kellum J, Shoji H, Foster D, Walker P. Endotoxemic sepsis: clinical features and therapy. J Transl Crit Care Med. 2022;4(1):13.","journal-title":"J Transl Crit Care Med"},{"issue":"3","key":"4533_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/cc13912","volume":"18","author":"C Ronco","year":"2014","unstructured":"Ronco C, Klein DJ. Polymyxin B hemoperfusion: a mechanistic perspective. Crit Care. 2014;18(3):309.","journal-title":"Crit Care"},{"issue":"23","key":"4533_CR5","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1001\/jama.2009.856","volume":"301","author":"DN Cruz","year":"2009","unstructured":"Cruz DN, Antonelli M, Fumagalli R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445\u201352.","journal-title":"JAMA"},{"issue":"5","key":"4533_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/01.shk.0000159930.87737.8a","volume":"23","author":"JL Vincent","year":"2005","unstructured":"Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock. 2005;23(5):400\u20135.","journal-title":"Shock"},{"issue":"6","key":"4533_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00134-015-3751-z","volume":"41","author":"DM Payen","year":"2015","unstructured":"Payen DM, Guilhot J, Launey Y, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41(6):975\u201384.","journal-title":"Intensive Care Med"},{"issue":"14","key":"4533_CR8","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2018.14618","volume":"320","author":"RP Dellinger","year":"2018","unstructured":"Dellinger RP, Bagshaw SM, Antonelli M, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455\u201363.","journal-title":"JAMA"},{"issue":"3","key":"4533_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000475982","volume":"44","author":"AD Romaschin","year":"2017","unstructured":"Romaschin AD, Obiezu-Forster CV, Shoji H, Klein DJ. Novel insights into the direct removal of endotoxin by polymyxin B hemoperfusion. Blood Purif. 2017;44(3):193\u20137.","journal-title":"Blood Purif"},{"issue":"12","key":"4533_CR10","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00134-018-5463-7","volume":"44","author":"DJ Klein","year":"2018","unstructured":"Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44(12):2205\u201312.","journal-title":"Intensive Care Med"},{"issue":"1","key":"4533_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13613-021-00928-z","volume":"11","author":"K Fujimori","year":"2021","unstructured":"Fujimori K, Tarasawa K, Fushimi K. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study. Ann Intensive Care. 2021;11(1):141.","journal-title":"Ann Intensive Care"},{"key":"4533_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2018.243","volume":"5","author":"M Hayakawa","year":"2018","unstructured":"Hayakawa M, Yamakawa K, Saito S, et al. Nationwide registry of sepsis patients in Japan focused on disseminated intravascular coagulation 2011\u20132013. Sci Data. 2018;5: 180243.","journal-title":"Sci Data"},{"issue":"4","key":"4533_CR13","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/01.CCM.0000050454.01978.3B","volume":"31","author":"MM Levy","year":"2003","unstructured":"Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM\/ESICM\/ACCP\/ATS\/SIS international sepsis definitions conference. Crit Care Med. 2003;31(4):1250\u20136.","journal-title":"Crit Care Med"},{"issue":"1","key":"4533_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13054-017-1712-3","volume":"21","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Kitamura T, Kiyomi F, et al. Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study. Crit Care. 2017;21(1):134.","journal-title":"Crit Care"},{"issue":"5","key":"4533_CR15","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1097\/CCM.0000000000000150","volume":"42","author":"M Iwagami","year":"2014","unstructured":"Iwagami M, Yasunaga H, Doi K, et al. Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis. Crit Care Med. 2014;42(5):1187\u201393.","journal-title":"Crit Care Med"},{"issue":"6","key":"4533_CR16","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/aje\/kwt312","volume":"179","author":"AD Shah","year":"2014","unstructured":"Shah AD, Bartlett JW, Carpenter J, Nicholas O, Hemingway H. Comparison of random forest and parametric imputation models for imputing missing data using MICE: a CALIBER study. Am J Epidemiol. 2014;179(6):764\u201374.","journal-title":"Am J Epidemiol"},{"key":"4533_CR17","unstructured":"grf: Generalized Random Forests 2023. https:\/\/cran.r-project.org\/web\/packages\/grf\/index.html. Accessed 27 May 2023."},{"key":"4533_CR18","unstructured":"Golub Capital Social Impact Lab. ML-based causal inference tutorial. 2021. https:\/\/bookdown.org\/halflearned\/ml-ci-tutorial\/ Accessed 27 May 2023."},{"issue":"523","key":"4533_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/01621459.2017.1319839","volume":"113","author":"S Wager","year":"2018","unstructured":"Wager S, Athey S. Estimation and inference of heterogeneous treatment effects using random forests. J Am Stat Assoc. 2018;113(523):1228\u201342.","journal-title":"J Am Stat Assoc"},{"issue":"27","key":"4533_CR20","doi-asserted-by":"publisher","first-page":"7353","DOI":"10.1073\/pnas.1510489113","volume":"113","author":"S Athey","year":"2016","unstructured":"Athey S, Imbens G. Recursive partitioning for heterogeneous causal effects. Proc Natl Acad Sci U S A. 2016;113(27):7353\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"4533_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1353\/obs.2019.0001","volume":"5","author":"S Athey","year":"2019","unstructured":"Athey S, Wager S. Estimating treatment effects with causal forests: an application. Observ Stud. 2019;5(2):37\u201351.","journal-title":"Observ Stud"},{"issue":"2","key":"4533_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1161\/CIRCULATIONAHA.122.062626","volume":"147","author":"K Inoue","year":"2023","unstructured":"Inoue K, Seeman TE, Horwich T, Budoff MJ, Watson KE. Heterogeneity in the association between the presence of coronary artery calcium and cardiovascular events: a machine-learning approach in the MESA study. Circulation. 2023;147(2):132\u201341.","journal-title":"Circulation"},{"issue":"1","key":"4533_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3982\/ECTA15732","volume":"89","author":"S Athey","year":"2021","unstructured":"Athey S, Wager S. Policy learning with observational data. Econometrica. 2021;89(1):133\u201361.","journal-title":"Econometrica"},{"key":"4533_CR24","unstructured":"Policytree: policy learning via doubly robust empirical welfare maximization over trees. 2022. https:\/\/cran.r-project.org\/web\/packages\/policytree\/index.html. Accessed 27 May 2023."},{"issue":"1","key":"4533_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/pan\/mpp036","volume":"18","author":"AN Glynn","year":"2010","unstructured":"Glynn AN, Quinn KM. An introduction to the augmented inverse propensity weighted estimator. Polit Anal. 2010;18(1):36\u201356.","journal-title":"Polit Anal"},{"issue":"8","key":"4533_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"issue":"20","key":"4533_CR27","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","volume":"321","author":"CW Seymour","year":"2019","unstructured":"Seymour CW, Kennedy JN, Wang S, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003\u201317.","journal-title":"JAMA"},{"key":"4533_CR28","first-page":"1","volume":"147","author":"JA Kellum","year":"2022","unstructured":"Kellum JA, Foster D, Walker PM. Endotoxemic shock: a molecular phenotype in sepsis. Nephron. 2022;147:1\u20134.","journal-title":"Nephron"},{"issue":"6","key":"4533_CR29","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.immuni.2019.11.005","volume":"51","author":"X Yang","year":"2019","unstructured":"Yang X, Cheng X, Tang Y, et al. Bacterial endotoxin activates the coagulation cascade through gasdermin D-dependent phosphatidylserine exposure. Immunity. 2019;51(6):983\u201396.","journal-title":"Immunity"},{"issue":"11","key":"4533_CR30","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181\u2013247.","journal-title":"Intensive Care Med"},{"issue":"11","key":"4533_CR31","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063\u2013143.","journal-title":"Crit Care Med"},{"issue":"3","key":"4533_CR32","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.3390\/ijerph18031333","volume":"18","author":"AR Alsaber","year":"2021","unstructured":"Alsaber AR, Pan J, Al-Hurban A. Handling complex missing data using random forest approach for an air quality monitoring dataset: a case study of Kuwait environmental data (2012 to 2018). Int J Environ Res Public Health. 2021;18(3):1333.","journal-title":"Int J Environ Res Public Health"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04533-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04533-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04533-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T00:32:02Z","timestamp":1700353922000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04533-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4533"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04533-3","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"30 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JAK and DMF are employees of Spectral Medical (Toronto, Canada). KD received a speaker\u2019s honorarium for lectures from Toray Industries, Inc. (Tokyo, Japan). No other disclosures were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol entitled \"Targeted therapy using Polymyxin B hemadsorption in patients with sepsis\" was approved by the Institutional Review Board of the University of Tokyo Hospital (No. 2022332NI) on February 27, 2023. This study was a secondary data analysis of de-identified data, and therefore, the requirement for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Financial competing interests: JK and DF are employees of Spectral Medical (Toronto, Canada). KD received a speaker\u2019s honorarium for lectures from Toray Industries, Inc. (Tokyo, Japan). No other disclosures were reported. Nonfinancial competing interests: DK and SK are institutional investigators in a clinical trial sponsored by Toray Industries, Inc. (Tokyo, Japan), but receive no payment. No other disclosures were reported.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"245"}}